Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2017

Shelley Wood

December 28, 2017

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Conference News AHA 2017

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Michael O'Riordan

November 17, 2017

News Daily News

More CVD and Stroke Drive Shorter Life Spans in African-Americans: AHA

Michael O'Riordan

October 24, 2017

News Industry News

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

October 02, 2017

News Daily News

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

Leah Lawrence

August 01, 2017

News

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

Michael O'Riordan

April 13, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

Advertisement

TCTMD’s Top 10 Most Popular Stories for December 2017

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

More CVD and Stroke Drive Shorter Life Spans in African-Americans: AHA

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content